Second Product Candidate Expected to Enter Clinic in First Half of 2021
Preclinical Data Underscore Treatment Potential for PBFT02 in Frontotemporal Dementia with Granulin (GRN) Mutations, a Devastating, Progressive Disorder Impacting Adults with No Approved Disease-Modifying Therapy Options
PHILADELPHIA, Jan. 28, 2021 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (Nasdaq: PASG), a genetic medicines company focused on developing transformative therapies for rare, monogenic central nervous system (CNS) disorders, today announced that the U.S. Food and Drug Administration (FDA) has cleared an investigational new drug (IND) application for PBFT02, an adeno-associated virus (AAV)-delivery gene therapy that is being studied for the treatment of patients with Frontotemporal Dementia (FTD) with granulin (GRN) mutations. FTD is a debilitating form of early onset dementia that currently has no approved disease-modifying therapies.
We are pleased to be advancing our second therapy into clinical development in our quest to bring transformative medicines to patients who need them, said Bruce Goldsmith, Ph.D., chief executive officer of Passage Bio. FTD can have a devastating impact on a persons quality of life and create a substantial caregiving and economic burden for families. We are excited to investigate the potential of PBFT02 as a treatment for FTD-GRN as we initiate our clinical development program in the coming months.
FTD is one of the more common causes of early-onset (midlife) dementia, causing impairment in behavior, language and executive function, and occurs at similar frequency to Alzheimers disease in patients younger than 65 years. In approximately 5 to 10 percent of individuals with FTD 3,000 to 6,000 in the United States the disease occurs because of mutations in the GRN gene, causing a deficiency of progranulin (PGRN). PGRN is a complex and highly conserved protein. The mechanism by which PGRN deficiency results in FTD is uncertain, but increasing evidence points to PGRNs role in lysosomal function. The rapid progression of FTD results in an average survival of eight years after onset of symptoms.
Passage Bio is developing PBFT02 to treat FTD-GRN as a single dose delivered via intra-cisterna magna (ICM) injection. The gene therapy utilizes an AAV1 viral vector to deliver a modified DNA encoding the GRN gene to a patient's cells. The goal of this vector and delivery approach is to provide higher than normal levels of PGRN to the central nervous system to overcome the progranulin deficiency in GRN mutation carriers, who have been observed to have reduced cerebrospinal fluid PGRN levels ranging from 30% to 50% of the PGRN levels observed in normal, mutation non-carriers.
Clinical Development of PBFT02 Supported by University of Pennsylvanias Gene Therapy Program (GTP) Pre-Clinical Data
Passage Bio is advancing PBFT02 into the clinic supported by preclinical data generated by its collaborator, University of Pennsylvanias Gene Therapy Program (GTP). The data, published in the peer-reviewed scientific journal Annals of Clinical and Translational Neurology, showed that a single administration of an optimized AAV containing the GRN gene resulted in elevated levels of PGRN in the brain and cerebral spinal fluid (CSF), reduced lysosomal storage lesions, normalized lysosomal enzyme expression and corrected microgliosis in a mouse model of progranulin deficiency. A single administration of PBFT02 via the optimized AAV1-GRN vector demonstrated transduction broadly across the brain, including a very high transduction of ependymal cells that line the ventricles of the brain and are involved with CSF production, resulting in CSF progranulin levels of more than 50-fold normal.
The FDA has granted an Orphan Drug designation for PBFT02 for the treatment of FTD-GRN.
Phase 1/2 Study Initiation Anticipated for 1H21
Passage Bio expects to initiate a Phase1/2 clinical trial for PBFT02 in the first half of 2021. The trial is designed as a dose-escalation study of a single ICM dose of PBFT02 in subjects with FTD and heterozygous mutations in the GRN gene. The primary endpoint of the Phase 1/2 study is safety and tolerability; secondary endpoints include CSF progranulin levels, disease biomarkers, and clinical outcome measure. Initial data from the trial is anticipated to potentially readout in late 2021 or early 2022, depending on the timing of when the first patient is treated in the study.
About Passage Bio
At Passage Bio (Nasdaq: PASG), we are on a mission to provide life-transforming gene therapies for patients with rare, monogenic CNS diseases that replace their suffering with boundless possibility, all while building lasting relationships with the communities we serve. Based in Philadelphia, PA, our company has established a strategic collaboration and licensing agreement with the renowned University of Pennsylvanias Gene Therapy Program to conduct our discovery and IND-enabling preclinical work. This provides our team with access to a broad portfolio of gene therapy candidates and future gene therapy innovations that we then pair with our deep clinical, regulatory, manufacturing and commercial expertise to rapidly advance our robust pipeline of optimized gene therapies into clinical testing. As we work with speed and tenacity, we are always mindful of patients who may be able to benefit from our therapies. More information is available at http://www.passagebio.com.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of, and made pursuant to the safe harbor provisions of, the Private Securities Litigation Reform Act of 1995, including, but not limited to: our expectations about timing and execution of anticipated milestones, including our planned IND submissions, initiation of clinical trials and the availability of clinical data from such trials; our expectations about our collaborators and partners ability to execute key initiatives; our expectations about manufacturing plans and strategies; our expectations about cash runway; and the ability of our lead product candidates to treat the underlying causes of their respective target monogenic CNS disorders. These forward-looking statements may be accompanied by such words as aim, anticipate, believe, could, estimate, expect, forecast, goal, intend, may, might, plan, potential, possible, will, would, and other words and terms of similar meaning. These statements involve risks and uncertainties that could cause actual results to differ materially from those reflected in such statements, including: our ability to develop and obtain regulatory approval for our product candidates; the timing and results of preclinical studies and clinical trials; risks associated with clinical trials, including our ability to adequately manage clinical activities, unexpected concerns that may arise from additional data or analysis obtained during clinical trials, regulatory authorities may require additional information or further studies, or may fail to approve or may delay approval of our drug candidates; the occurrence of adverse safety events; the risk that positive results in a preclinical study or clinical trial may not be replicated in subsequent trials or success in early stage clinical trials may not be predictive of results in later stage clinical trials; failure to protect and enforce our intellectual property, and other proprietary rights; our dependence on collaborators and other third parties for the development and manufacture of product candidates and other aspects of our business, which are outside of our full control; risks associated with current and potential delays, work stoppages, or supply chain disruptions caused by the coronavirus pandemic; and the other risks and uncertainties that are described in the Risk Factors section in documents the company files from time to time with the Securities and Exchange Commission (SEC), and other reports as filed with the SEC. Passage Bio undertakes no obligation to publicly update any forward-looking statement, whether written or oral, that may be made from time to time, whether as a result of new information, future developments or otherwise.
For further information, please contact:
Passage Bio Investors:
Sarah McCabe and Zofia MitaStern Investor Relations, Inc.212-362-1200sarah.mccabe@sternir.com Zofia.mita@sternir.com
Passage Bio Media:
Gwen FisherPassage Bio215-407-1548gfisher@passagebio.com
- 001 Faulty Circuits (preview) [Last Updated On: April 7th, 2010] [Originally Added On: April 7th, 2010]
- 002 Faulty Circuits (preview) [Last Updated On: April 7th, 2010] [Originally Added On: April 7th, 2010]
- 003 Rare flowers and common herbal supplements get unmasked with plant DNA barcoding [Last Updated On: April 20th, 2010] [Originally Added On: April 20th, 2010]
- 004 Rare flowers and common herbal supplements get unmasked with plant DNA barcoding [Last Updated On: April 20th, 2010] [Originally Added On: April 20th, 2010]
- 005 Biomarker Studies Could Realize Goal of More Effective and Personalized Cancer Medicine [Last Updated On: April 27th, 2010] [Originally Added On: April 27th, 2010]
- 006 Biomarker Studies Could Realize Goal of More Effective and Personalized Cancer Medicine [Last Updated On: April 27th, 2010] [Originally Added On: April 27th, 2010]
- 007 Schizophrenia shares genetic links with autism, genome study shows [Last Updated On: May 12th, 2010] [Originally Added On: May 12th, 2010]
- 008 Schizophrenia shares genetic links with autism, genome study shows [Last Updated On: May 12th, 2010] [Originally Added On: May 12th, 2010]
- 009 Alzheimer's: Forestalling the Darkness with New Approaches (preview) [Last Updated On: May 28th, 2010] [Originally Added On: May 28th, 2010]
- 010 Alzheimer's: Forestalling the Darkness with New Approaches (preview) [Last Updated On: May 28th, 2010] [Originally Added On: May 28th, 2010]
- 011 Large-Scale Autism Study Reveals Disorder's Genetic Complexity [Last Updated On: June 12th, 2010] [Originally Added On: June 12th, 2010]
- 012 Large-Scale Autism Study Reveals Disorder's Genetic Complexity [Last Updated On: June 12th, 2010] [Originally Added On: June 12th, 2010]
- 013 Cancer Therapy Goes Viral: Progress Is Made Tackling Tumors with Viruses [Last Updated On: June 24th, 2010] [Originally Added On: June 24th, 2010]
- 014 Cancer Therapy Goes Viral: Progress Is Made Tackling Tumors with Viruses [Last Updated On: June 24th, 2010] [Originally Added On: June 24th, 2010]
- 015 Vaccines Derived from Patients' Tumor Cells Are Individualizing Cancer Treatment [Last Updated On: June 26th, 2010] [Originally Added On: June 26th, 2010]
- 016 Vaccines Derived from Patients' Tumor Cells Are Individualizing Cancer Treatment [Last Updated On: June 26th, 2010] [Originally Added On: June 26th, 2010]
- 017 A genome story: 10th anniversary commentary by Francis Collins [Last Updated On: June 29th, 2010] [Originally Added On: June 29th, 2010]
- 018 A genome story: 10th anniversary commentary by Francis Collins [Last Updated On: June 29th, 2010] [Originally Added On: June 29th, 2010]
- 019 Hair Trigger: How a Cell's Primary Cilium Functions as a Molecular Antenna [Last Updated On: June 30th, 2010] [Originally Added On: June 30th, 2010]
- 020 Hair Trigger: How a Cell's Primary Cilium Functions as a Molecular Antenna [Last Updated On: June 30th, 2010] [Originally Added On: June 30th, 2010]
- 021 DNA Drugs Come of Age (preview) [Last Updated On: July 16th, 2010] [Originally Added On: July 16th, 2010]
- 022 DNA Drugs Come of Age (preview) [Last Updated On: July 16th, 2010] [Originally Added On: July 16th, 2010]
- 023 2 Genes Linked to Embryonic Brain Impairment in Down's Syndrome [Last Updated On: July 22nd, 2010] [Originally Added On: July 22nd, 2010]
- 024 2 Genes Linked to Embryonic Brain Impairment in Down's Syndrome [Last Updated On: July 22nd, 2010] [Originally Added On: July 22nd, 2010]
- 025 Stem Cells from Reprogrammed Adult Cells Found to Bring Along Genetic Defects of Their Donors [Last Updated On: October 11th, 2010] [Originally Added On: October 11th, 2010]
- 026 Was Darwin a Punk? A Q&A with Punker-Paleontologist Greg Graffin [Last Updated On: October 11th, 2010] [Originally Added On: October 11th, 2010]
- 027 Parkinsonian Power Failure: Neuron Degeneration May Be Caused by a Cellular Energy System Breakdown [Last Updated On: October 11th, 2010] [Originally Added On: October 11th, 2010]
- 028 Stem Cells from Reprogrammed Adult Cells Found to Bring Along Genetic Defects of Their Donors [Last Updated On: October 11th, 2010] [Originally Added On: October 11th, 2010]
- 029 Was Darwin a Punk? A Q&A with Punker-Paleontologist Greg Graffin [Last Updated On: October 11th, 2010] [Originally Added On: October 11th, 2010]
- 030 Parkinsonian Power Failure: Neuron Degeneration May Be Caused by a Cellular Energy System Breakdown [Last Updated On: October 11th, 2010] [Originally Added On: October 11th, 2010]
- 031 Desperation Drives Parents to Dubious Autism Treatments (preview) [Last Updated On: October 13th, 2010] [Originally Added On: October 13th, 2010]
- 032 Desperation Drives Parents to Dubious Autism Treatments (preview) [Last Updated On: October 17th, 2010] [Originally Added On: October 17th, 2010]
- 033 Revolution Postponed: Why the Human Genome Project Has Been Disappointing (preview) [Last Updated On: October 21st, 2010] [Originally Added On: October 21st, 2010]
- 034 Controlling the Brain with Light (preview) [Last Updated On: November 7th, 2010] [Originally Added On: November 7th, 2010]
- 035 Optogenetics: Controlling the Brain with Light [Extended Version] [Last Updated On: November 7th, 2010] [Originally Added On: November 7th, 2010]
- 036 Clear New Insights into the Genetics of Depression [Last Updated On: November 7th, 2010] [Originally Added On: November 7th, 2010]
- 037 TEDMED 2010: Technology and the people [Last Updated On: November 7th, 2010] [Originally Added On: November 7th, 2010]
- 038 Bacteria, the anti-cancer soldier [Last Updated On: November 7th, 2010] [Originally Added On: November 7th, 2010]
- 039 Revolution Postponed: Why the Human Genome Project Has Been Disappointing (preview) [Last Updated On: November 7th, 2010] [Originally Added On: November 7th, 2010]
- 040 Controlling the Brain with Light (preview) [Last Updated On: November 7th, 2010] [Originally Added On: November 7th, 2010]
- 041 Optogenetics: Controlling the Brain with Light [Extended Version] [Last Updated On: November 7th, 2010] [Originally Added On: November 7th, 2010]
- 042 Clear New Insights into the Genetics of Depression [Last Updated On: November 7th, 2010] [Originally Added On: November 7th, 2010]
- 043 TEDMED 2010: Technology and the people [Last Updated On: November 7th, 2010] [Originally Added On: November 7th, 2010]
- 044 Bacteria, the anti-cancer soldier [Last Updated On: November 7th, 2010] [Originally Added On: November 7th, 2010]
- 045 Scientific regress: When science goes backward [Last Updated On: November 29th, 2010] [Originally Added On: November 29th, 2010]
- 046 Can You Live Forever? Maybe Not--But You Can Have Fun Trying [Last Updated On: January 1st, 2011] [Originally Added On: January 1st, 2011]
- 047 How to Fix the Obesity Crisis (preview) [Last Updated On: January 22nd, 2011] [Originally Added On: January 22nd, 2011]
- 048 Scientific regress: When science goes backward [Last Updated On: February 14th, 2011] [Originally Added On: February 14th, 2011]
- 049 Can You Live Forever? Maybe Not--But You Can Have Fun Trying [Last Updated On: February 14th, 2011] [Originally Added On: February 14th, 2011]
- 050 How to Fix the Obesity Crisis (preview) [Last Updated On: February 14th, 2011] [Originally Added On: February 14th, 2011]
- 051 Personalizing cancer medicine [Last Updated On: February 14th, 2011] [Originally Added On: February 14th, 2011]
- 052 New Salmonella strain delivers gene-based therapy to fight virus in mice [Last Updated On: February 14th, 2011] [Originally Added On: February 14th, 2011]
- 053 Personalizing cancer medicine [Last Updated On: February 14th, 2011] [Originally Added On: February 14th, 2011]
- 054 New Salmonella strain delivers gene-based therapy to fight virus in mice [Last Updated On: February 14th, 2011] [Originally Added On: February 14th, 2011]
- 055 Steps toward a Bionic Eye [Last Updated On: February 18th, 2011] [Originally Added On: February 18th, 2011]
- 056 Steps toward a Bionic Eye [Last Updated On: February 20th, 2011] [Originally Added On: February 20th, 2011]
- 057 Giving HIV a Poor Reception: New AIDS Treatment Tinkers with Immune Cell Genes [Last Updated On: March 6th, 2011] [Originally Added On: March 6th, 2011]
- 058 Giving HIV a Poor Reception: New AIDS Treatment Tinkers with Immune Cell Genes [Last Updated On: March 6th, 2011] [Originally Added On: March 6th, 2011]
- 059 Smaller, cheaper, faster: Does Moore's law apply to solar cells? [Last Updated On: March 27th, 2011] [Originally Added On: March 27th, 2011]
- 060 Smaller, cheaper, faster: Does Moore's law apply to solar cells? [Last Updated On: March 27th, 2011] [Originally Added On: March 27th, 2011]
- 061 New Drugs for Hepatitis C on the Horizon [Last Updated On: April 10th, 2011] [Originally Added On: April 10th, 2011]
- 062 Can we capture all of the world's carbon emissions? [Last Updated On: April 10th, 2011] [Originally Added On: April 10th, 2011]
- 063 New Drugs for Hepatitis C on the Horizon [Last Updated On: April 10th, 2011] [Originally Added On: April 10th, 2011]
- 064 Can we capture all of the world's carbon emissions? [Last Updated On: April 10th, 2011] [Originally Added On: April 10th, 2011]
- 065 Drug-resistant genes found in cholera and dysentery strains in New Delhi water supply [Last Updated On: May 1st, 2011] [Originally Added On: May 1st, 2011]
- 066 Fast Track to Vaccines: How Systems Biology Speeds Drug Development (preview) [Last Updated On: May 1st, 2011] [Originally Added On: May 1st, 2011]
- 067 Drug-resistant genes found in cholera and dysentery strains in New Delhi water supply [Last Updated On: May 1st, 2011] [Originally Added On: May 1st, 2011]
- 068 Fast Track to Vaccines: How Systems Biology Speeds Drug Development (preview) [Last Updated On: May 1st, 2011] [Originally Added On: May 1st, 2011]
- 069 Autism's Tangled Genetics Full of Rare and Varied Mutations [Last Updated On: June 19th, 2011] [Originally Added On: June 19th, 2011]
- 070 A New Look at Obsessive-Compulsive Disorder (preview) [Last Updated On: June 19th, 2011] [Originally Added On: June 19th, 2011]
- 071 Autism's Tangled Genetics Full of Rare and Varied Mutations [Last Updated On: June 19th, 2011] [Originally Added On: June 19th, 2011]
- 072 A New Look at Obsessive-Compulsive Disorder (preview) [Last Updated On: June 19th, 2011] [Originally Added On: June 19th, 2011]
- 073 Close Encounters of Science and Medicine [Last Updated On: July 3rd, 2011] [Originally Added On: July 3rd, 2011]
- 074 Close Encounters of Science and Medicine [Last Updated On: July 3rd, 2011] [Originally Added On: July 3rd, 2011]
- 075 New Report Details Uphill Battle to Solve the U.S.'s Pain Problem [Last Updated On: July 24th, 2011] [Originally Added On: July 24th, 2011]
- 076 New Report Details Uphill Battle to Solve the U.S.'s Pain Problem [Last Updated On: July 24th, 2011] [Originally Added On: July 24th, 2011]
- 077 A Breath of Fresh Air: New Hope for Cystic Fibrosis Treatment (preview) [Last Updated On: August 7th, 2011] [Originally Added On: August 7th, 2011]
- 078 A Breath of Fresh Air: New Hope for Cystic Fibrosis Treatment (preview) [Last Updated On: August 7th, 2011] [Originally Added On: August 7th, 2011]
- 079 Gene therapy improves stem cell transplantation - Video [Last Updated On: October 13th, 2011] [Originally Added On: October 13th, 2011]
- 080 THE NEW MORGELLONS HAIR - Video [Last Updated On: October 18th, 2011] [Originally Added On: October 18th, 2011]